CASTLE BIOSCIENCES, INC. (CSTL) Spending and interest coverage
- R&D / revenue · 12 months: Value 15.52%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 12.56%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 15.52% | Research and development expense / revenue. Period ending 2026-06-30. $55.45M ÷ $357.28M × 100 ≈ 15.52% |
| Stock-based compensation / revenue · 12 months | 12.56% | Share-based compensation / revenue. Period ending 2026-06-30. $44.87M ÷ $357.28M × 100 ≈ 12.56% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 55.45M USD | Research and Development Expense |
| Revenue | 357.28M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 44.87M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -32.11M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $55.45M | $357.28M | $44.87M | $-32.11M | (m) | 15.52% | 12.56% | (m) | (m) |
| 2026-03-31 | $53.69M | $339.92M | $44.49M | $-33.29M | (m) | 15.79% | 13.09% | (m) | (m) |
| 2025-12-31 | $51.85M | $344.23M | $45.89M | $-42.81M | (m) | 15.06% | 13.33% | (m) | (m) |
| 2025-09-30 | $50.11M | $343.53M | $45.93M | $-34.93M | (m) | 14.59% | 13.37% | (m) | (m) |
| 2025-06-30 | $49.47M | $346.27M | $46.85M | $-23.05M | (m) | 14.29% | 13.53% | (m) | (m) |
| 2025-03-31 | $50.82M | $347.08M | $48.82M | $-13.79M | (m) | 14.64% | 14.07% | (m) | (m) |
| 2024-12-31 | $52.04M | $332.07M | $50.32M | $8.67M | (m) | 15.67% | 15.15% | (m) | (m) |
| 2024-09-30 | $53.26M | $311.88M | $50.68M | $-1.04M | $423.00K | 17.08% | 16.25% | -2.45× | Reported |
| 2024-06-30 | $53.86M | $287.59M | $50.70M | $-15.76M | $233.00K | 18.73% | 17.63% | -67.63× | Reported |
| 2024-03-31 | $53.03M | $250.72M | $50.37M | $-41.93M | $21.00K | 21.15% | 20.09% | -1996.48× | Reported |
| 2023-12-31 | $53.62M | $219.79M | $51.22M | $-67.98M | $11.00K | 24.40% | 23.30% | -6179.73× | Reported |
| 2023-09-30 | $51.93M | $192.01M | $49.34M | $-85.15M | $13.00K | 27.05% | 25.70% | -6550.08× | Reported |
| 2023-06-30 | $49.92M | $167.52M | $45.49M | $-97.05M | $17.00K | 29.80% | 27.16% | -5708.65× | Reported |
| 2023-03-31 | $48.53M | $152.22M | $41.43M | $-79.86M | $18.00K | 31.88% | 27.21% | -4436.72× | Reported |
| 2022-12-31 | $44.90M | $137.04M | $36.32M | $-72.86M | $17.00K | 32.77% | 26.50% | -4285.59× | Reported |
| 2022-09-30 | $43.04M | $123.74M | $33.25M | $-65.19M | $14.00K | 34.78% | 26.87% | -4656.71× | Reported |
| 2022-06-30 | $39.63M | $110.20M | $29.26M | $-55.47M | $8.00K | 35.96% | 26.55% | -6934.00× | Reported |
| 2022-03-31 | $34.50M | $98.12M | $25.25M | $-60.31M | $4.00K | 35.16% | 25.73% | -15077.75× | Reported |
| 2021-12-31 | $29.65M | $94.08M | $21.74M | $-40.08M | $1.00K | 31.51% | 23.11% | -40079.00× | Reported |
| 2021-09-30 | $24.78M | $86.34M | $17.85M | $-27.94M | $395.00K | 28.70% | 20.67% | -70.73× | Reported |
| 2021-06-30 | $20.34M | $78.09M | $14.76M | $-20.03M | $1.10M | 26.05% | 18.90% | -18.19× | Reported |
| 2021-03-31 | $16.25M | $68.04M | $11.64M | $-11.86M | $1.87M | 23.88% | 17.11% | -6.34× | Reported |
| 2020-12-31 | $13.26M | $62.65M | $8.31M | $-6.54M | $2.63M | 21.16% | 13.26% | -2.48× | Reported |
| 2020-09-30 | $11.83M | $62.98M | $6.06M | $-897.00K | $3.00M | 18.79% | 9.62% | -0.30× | Reported |
| 2020-06-30 | $10.29M | $62.54M | $4.17M | $7.43M | $3.39M | 16.45% | 6.67% | 2.19× | Reported |
| 2020-03-31 | $8.90M | $60.57M | $2.66M | $8.69M | $4.31M | 14.70% | 4.39% | 2.01× | Reported |
| 2019-12-31 | $7.38M | $51.87M | $1.25M | $7.33M | $4.57M | 14.24% | 2.41% | 1.60× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $27.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.85M | $22.79M | $294.00K | $-3.84M | $2.27M | 21.30% | 1.29% | -1.69× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |